E De Luca, N Gori, A Chiricozzi, A Di Stefani, K Peris
{"title":"upadacitinib治疗的特应性皮炎患者的眼周传染性软疣。","authors":"E De Luca, N Gori, A Chiricozzi, A Di Stefani, K Peris","doi":"10.1080/09546634.2022.2104445","DOIUrl":null,"url":null,"abstract":"A 33-year-old patient, under treatment with upadacitinib for atopic dermatitis (AD), was examined for multiple, bilateral, papular, periocular lesions. The patient had AD since the age of 2 years and had been previously treated with topical and sys-temic agents including corticosteroids, cyclosporine, methotrexate and dupilumab. With dupilumab, the AD flared with involvement of the head and neck. Biologic treatment was inter-rupted, and upadacitinib at the dosage of 30mg/day was pre-scribed, achieving complete remission of AD signs and symptoms after 2 weeks. lymphocyte","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib.\",\"authors\":\"E De Luca, N Gori, A Chiricozzi, A Di Stefani, K Peris\",\"doi\":\"10.1080/09546634.2022.2104445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 33-year-old patient, under treatment with upadacitinib for atopic dermatitis (AD), was examined for multiple, bilateral, papular, periocular lesions. The patient had AD since the age of 2 years and had been previously treated with topical and sys-temic agents including corticosteroids, cyclosporine, methotrexate and dupilumab. With dupilumab, the AD flared with involvement of the head and neck. Biologic treatment was inter-rupted, and upadacitinib at the dosage of 30mg/day was pre-scribed, achieving complete remission of AD signs and symptoms after 2 weeks. lymphocyte\",\"PeriodicalId\":15639,\"journal\":{\"name\":\"Journal of Dermatological Treatment\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatological Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2022.2104445\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2104445","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib.
A 33-year-old patient, under treatment with upadacitinib for atopic dermatitis (AD), was examined for multiple, bilateral, papular, periocular lesions. The patient had AD since the age of 2 years and had been previously treated with topical and sys-temic agents including corticosteroids, cyclosporine, methotrexate and dupilumab. With dupilumab, the AD flared with involvement of the head and neck. Biologic treatment was inter-rupted, and upadacitinib at the dosage of 30mg/day was pre-scribed, achieving complete remission of AD signs and symptoms after 2 weeks. lymphocyte
期刊介绍:
The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.